Preliminary results after application of absorbable metal stents in patients with critical limb ischemia
Preliminary results after application of absorbable metal stents in patients with critical limb ischemia
复制标题
DOI：
10.1583/04-1349r.1
复制
发表时间：
2005-02-01
影响因子：
2.6
通讯作者：
Heublein, B
中科院分区：
文献类型：
--
作者：
Peeters, P;Bosiers, M;Heublein, B
目的：报道一种新研制的可吸收金属支架(AMS)治疗严重肢体缺血(CLI)患者的初步3个月随访结果。方法：2003年12月至2004年1月，20例(男性10例，平均76岁，年龄59~96岁)重度(80%~100%)症状性严重肢体缺血(CLI)患者接受了1~2个AMS装置的次优血管成形术。所有患者在出院时、1个月和3个月进行临床检查和彩色血流双功成像。结果：20例患者血管造影均获得成功。1例患者在围手术期死亡(与手术无关)。术后3个月临床通畅率为89.5%(17/19)。所有患者均无大小截肢，肢体保留率为100%。在为期3个月的评估中，卢瑟福班的平均进步为2.3分。术后和术后1个月的彩色双功超声和磁共振图像的比较清楚地显示了AMS的持续吸收过程。结论：术后3个月的初步临床通畅率和肢体保留率表明，这些AMS装置在治疗CLI患者膝关节以下病变方面具有潜在的前景。
Purpose: To report the preliminary 3-month follow-up of a recently developed absorbable metal stent (AMS) for treatment of infrapopliteal lesions in patients with critical limb ischemia (CLI).Methods: Between December 2003 and January 2004, 20 patients (10 men; mean age 76 years, range 59-96) with symptomatic critical limb ischemia (CLI) due to high-grade (80% to 100%) infrapopliteal stenoses received 1 or 2 AMS devices for suboptimal angioplasty. Clinical examination and color-flow duplex imaging were performed in all patients at discharge and at 1 and 3 months.Results: Angiographic procedural success was achieved in all 20 patients. One patient died (non-procedure-related) during the periprocedural period. Three months after the procedure, primary clinical patency was 89.5% (17/19). No major or minor amputation was necessary in any of the patients, yielding a limb salvage rate of 100%. The average improvement in Rutherford class was 2.3 at the 3-month assessment. A comparison of postprocedural and 1-month color-flow duplex ultrasound and magnetic resonance images clearly indicated the ongoing absorption process of the AMS.Conclusions: After 3 months, the primary clinical patency and limb salvage rates suggest a potentially promising performance of these AMS devices in the treatment of below-knee lesions in CLI patients.